Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Farmers Insurance
Argus Health
Queensland Health
Fuji
UBS
Cerilliant
Johnson and Johnson
Deloitte
Fish and Richardson

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,994,329

« Back to Dashboard

Which drugs does patent 5,994,329 protect, and when does it expire?


Patent 5,994,329 protects ACTONEL WITH CALCIUM (COPACKAGED), ACTONEL, FOSAMAX PLUS D, and FOSAMAX, and is included in four NDAs. There have been zero Paragraph IV challenges on Actonel, Fosamax Plus D, and .

Protection for ACTONEL WITH CALCIUM (COPACKAGED) has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-six patent family members in forty countries.

Summary for Patent: 5,994,329

Title: Method for inhibiting bone resorption
Abstract:Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Inventor(s): Daifotis; Anastasia G. (Westfield, NJ), Santora, II; Arthur C. (Watchung, NJ), Yates; A. John (Westfield, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/134,214
Patent Claim Types:
see list of patent claims
Use; Dosage form; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Warner Chilcott
ACTONEL WITH CALCIUM (COPACKAGED)
calcium carbonate; risedronate sodium
TABLET, TABLET;ORAL021823-001Aug 12, 2005DISCNYesNo► Subscribe► SubscribeY
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-003May 25, 2002ABRXYesYes► Subscribe► SubscribeY
Merck
FOSAMAX PLUS D
alendronate sodium; cholecalciferol
TABLET;ORAL021762-001Apr 7, 2005RXYesNo► Subscribe► SubscribeY
Merck
FOSAMAX
alendronate sodium
SOLUTION;ORAL021575-001Sep 17, 2003DISCNYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,994,329

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,015,801 Method for inhibiting bone resorption► Subscribe
6,465,443 Method for inhibiting bone resorption► Subscribe
6,333,316 Method for inhibiting bone resorption► Subscribe
6,544,967 Method for inhibiting bone resorption► Subscribe
6,225,294 Method for inhibiting bone resorption► Subscribe
6,432,932 Method for inhibiting bone resorption► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,994,329

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong1024166► Subscribe
United Kingdom9717850► Subscribe
United Kingdom9717590► Subscribe
United Kingdom2336311► Subscribe
United Kingdom9819243► Subscribe
Spain2253136► Subscribe
Spain2269014► Subscribe
Spain2164447► Subscribe
European Patent Office1175904► SubscribePA2007007Lithuania► Subscribe
European Patent Office1175904► SubscribeCA 2007 00045Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Cerilliant
Argus Health
Chubb
Daiichi Sankyo
McKesson
Farmers Insurance
US Department of Justice
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot